Apellis Pharmaceuticals (APLS) Expected to Announce Quarterly Earnings on Wednesday

Apellis Pharmaceuticals (NASDAQ:APLS) is projected to announce its Q1 2026 results before the market opens on Wednesday, May 6th. Analysts expect the company to announce earnings of ($0.38) per share and revenue of $203.5830 million for the quarter. Investors may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 8:30 AM ET.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its earnings results on Tuesday, February 24th. The company reported $0.47 EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.86. Apellis Pharmaceuticals had a return on equity of 8.20% and a net margin of 2.23%.The firm had revenue of $199.91 million during the quarter, compared to the consensus estimate of $199.28 million. During the same quarter in the previous year, the company posted ($0.29) earnings per share. The company’s revenue was down 5.9% compared to the same quarter last year. On average, analysts expect Apellis Pharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Apellis Pharmaceuticals Trading Up 0.0%

Apellis Pharmaceuticals stock opened at $40.97 on Tuesday. The company has a quick ratio of 2.70, a current ratio of 3.14 and a debt-to-equity ratio of 0.98. Apellis Pharmaceuticals has a 52 week low of $16.10 and a 52 week high of $41.00. The company has a market capitalization of $5.24 billion, a price-to-earnings ratio of 315.18 and a beta of -0.24. The stock has a 50-day moving average price of $29.22 and a 200 day moving average price of $25.24.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. State Board of Administration of Florida Retirement System lifted its holdings in Apellis Pharmaceuticals by 0.6% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 96,125 shares of the company’s stock valued at $2,415,000 after acquiring an additional 530 shares during the period. Xponance LLC lifted its holdings in Apellis Pharmaceuticals by 3.9% in the fourth quarter. Xponance LLC now owns 18,164 shares of the company’s stock valued at $456,000 after acquiring an additional 681 shares during the period. Treasurer of the State of North Carolina lifted its holdings in Apellis Pharmaceuticals by 2.8% in the second quarter. Treasurer of the State of North Carolina now owns 50,358 shares of the company’s stock valued at $872,000 after acquiring an additional 1,353 shares during the period. Osaic Holdings Inc. lifted its holdings in Apellis Pharmaceuticals by 141.2% in the second quarter. Osaic Holdings Inc. now owns 2,682 shares of the company’s stock valued at $47,000 after acquiring an additional 1,570 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Apellis Pharmaceuticals by 11.4% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 21,317 shares of the company’s stock valued at $482,000 after acquiring an additional 2,189 shares during the period. 96.29% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on APLS shares. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $41.00 target price (up from $37.00) on shares of Apellis Pharmaceuticals in a report on Wednesday, April 1st. Barclays lifted their target price on Apellis Pharmaceuticals from $24.00 to $41.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 1st. Royal Bank Of Canada decreased their target price on Apellis Pharmaceuticals from $22.00 to $21.00 and set a “sector perform” rating for the company in a report on Wednesday, February 25th. Cantor Fitzgerald downgraded Apellis Pharmaceuticals from an “overweight” rating to a “hold” rating in a report on Tuesday, March 31st. Finally, The Goldman Sachs Group reaffirmed a “sell” rating and set a $19.00 target price on shares of Apellis Pharmaceuticals in a report on Monday, January 12th. Three investment analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Apellis Pharmaceuticals presently has an average rating of “Hold” and an average price target of $34.89.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.